Innovative Computerized Dystrophin Quantification Method Based on Spectral Confocal Microscopy
暂无分享,去创建一个
D. Cuadras | C. Ortez | L. Matalonga | C. Jiménez-Mallebrera | C. Jou | D. Natera-de Benito | A. Nascimento | M. Roldán | L. Carrera | A. Codina | Jesus Marquez | R. Planas | Jesica Exposito | Josep M. Porta
[1] F. Muntoni,et al. High-Throughput Digital Image Analysis Reveals Distinct Patterns of Dystrophin Expression in Dystrophinopathy Patients , 2021, Journal of neuropathology and experimental neurology.
[2] K. Flanigan,et al. Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies , 2021, Neuromuscular Disorders.
[3] J. Liao,et al. Novel Intronic Mutations Introduce Pseudoexons in DMD That Cause Muscular Dystrophy in Patients , 2021, Frontiers in Genetics.
[4] M. Falzarano,et al. Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy , 2021, Journal of clinical medicine.
[5] Cecilia Jimenez-Mallebrera,et al. Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy , 2020, Frontiers in Neurology.
[6] E. Hoffman,et al. Absolute Quantification of Dystrophin Protein in Human Muscle Biopsies using Parallel Reaction Monitoring (PRM). , 2020, Journal of mass spectrometry : JMS.
[7] F. Authier,et al. Automated image-analysis method for the quantification of fiber morphometry and fiber type population in human skeletal muscle , 2019, Skeletal Muscle.
[8] J. Paul,et al. Misleading Westerns: Common Quantification Mistakes in Western Blot Densitometry and Proposed Corrective Measures , 2019, BioMed research international.
[9] S. Takeda,et al. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches , 2019, Journal of personalized medicine.
[10] E. Hoffman,et al. Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology , 2019, Journal of neuromuscular diseases.
[11] P. Shieh. Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy , 2018, Neurotherapeutics.
[12] N. Datson,et al. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy , 2018, PloS one.
[13] F. Muntoni,et al. A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples , 2018, PloS one.
[14] A. Milici,et al. Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification , 2017, Toxicologic pathology.
[15] J. Kleijnen,et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review , 2017, Orphanet Journal of Rare Diseases.
[16] E. Madarász,et al. Enhanced detection with spectral imaging fluorescence microscopy reveals tissue- and cell-type-specific compartmentalization of surface-modified polystyrene nanoparticles , 2016, Journal of Nanobiotechnology.
[17] M. van Putten,et al. Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods. , 2016, Journal of neuromuscular diseases.
[18] K. Bushby,et al. The importance of genetic diagnosis for Duchenne muscular dystrophy , 2016, Journal of Medical Genetics.
[19] M. Baiget,et al. DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations , 2015, PloS one.
[20] Eric P. Hoffman,et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy , 2015, Proceedings of the National Academy of Sciences.
[21] F. Muntoni,et al. Dystrophin quantification , 2014, Neurology.
[22] B. Yoon,et al. Clinical, immunohistochemical, Western blot, and genetic analysis in dystrophinopathy , 2013, Journal of Clinical Neuroscience.
[23] A. Toutain,et al. Genetic and clinical specificity of 26 symptomatic carriers for dystrophinopathies at pediatric age , 2013, European Journal of Human Genetics.
[24] R. Borlinghaus. The white confocal , 2012 .
[25] Thorsten Bergmann,et al. Evaluation and quantification of spectral information in tissue by confocal microscopy , 2012, Journal of biomedical optics.
[26] K. Flanigan,et al. Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens , 2012, Neuropathology and applied neurobiology.
[27] Ping-Chang Yang,et al. Western Blot: Technique, Theory, and Trouble Shooting , 2012, North American journal of medical sciences.
[28] Kevin M Flanigan,et al. The Muscular Dystrophies , 1999, Seminars in Neurology.
[29] Jennifer C. Waters,et al. Accuracy and precision in quantitative fluorescence microscopy , 2009, The Journal of cell biology.
[30] Francesco Muntoni,et al. Dystrophin and mutations: one gene, several proteins, multiple phenotypes , 2003, The Lancet Neurology.
[31] Joe G Hollyfield,et al. Spectral profiling of autofluorescence associated with lipofuscin, Bruch's Membrane, and sub-RPE deposits in normal and AMD eyes. , 2002, Investigative ophthalmology & visual science.
[32] C. V. D. van de Lest,et al. Elimination of autofluorescence in immunofluorescence microscopy with digital image processing. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[33] A. Monaco,et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.